NOTCH3 and undifferentiated pancreatic carcinoma: Emerging evidence indicates that Notch3 is associated with PD-L1 and co-expressed in pancreatic sarcomatoid carcinoma, suggesting that combined targeting of PD-L1 and Notch3 may represent a promising therapeutic strategy [34].